Literature DB >> 2418583

Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB.

K Kitamura, J Namazue, H Campo-Vera, T Ogino, K Yamanishi.   

Abstract

Glycoprotein gp3 (64K) is one of the major proteins specified by varicella-zoster virus (VZV). This glycoprotein was purified on an immunoadsorbent consisting of monoclonal antibody (clone 8) against gp3 linked to protein A-Sepharose. Rabbits were then immunized with the purified antigen to obtain monospecific antisera against gp3. The monospecific antisera and monoclonal antibody immunoprecipitated polypeptides with the same molecular weights of approximately 64,000 (64K), 106K, and 116K from a lysate of labeled cells infected with VZV. The monoclonal antibodies against gp3 did not have neutralizing activity against VZV, but anti-gp3 monospecific sera neutralized VZV infectivity. The antigenic relation of VZV to herpes simplex virus (HSV) was investigated by the immunofluorescent test, immunoprecipitation followed by analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the neutralizing antibody test with monoclonal antibodies and monospecific antisera. In the indirect immunofluorescent test, the cytoplasm of cells infected with HSV-type 1 or HSV-type 2 was stained with anti-gp3 monospecific antiserum but not with anti-gp3 monoclonal antibodies. This serum also precipitated the polypeptides of HSV-type 1 and HSV-type 2 with molecular weight of approximately 120,000, possibly corresponding to gB of HSV-1 or HSV-2, and this immunoprecipitation was blocked by anti-gB monoclonal antibody. However, anti-gp3 monospecific antisera did not neutralize either HSV-type 1 or HSV-type 2 infectivity. These results suggest that gp3 induces neutralizing antibody against VZV and that it also has a cross-reacting antigenic determinant with gB of HSV.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418583     DOI: 10.1016/0042-6822(86)90088-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Specificity of skin test with varicella-zoster virus antigen in varicella-zoster and herpes simplex virus infections.

Authors:  K Baba; K Shiraki; T Kanesaki; K Yamanishi; P L Ogra; H Yabuuchi; M Takahashi
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

2.  Bovine herpesvirus type 1 gp87 mediates both attachment of virions to susceptible cells and hemagglutination.

Authors:  K Okazaki; E Honda; T Minetoma; T Kumagai
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

3.  Complete replication in vitro of tobacco mosaic virus RNA by a template-dependent, membrane-bound RNA polymerase.

Authors:  T A Osman; K W Buck
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.

Authors:  M Gong; T Ooka; T Matsuo; E Kieff
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

5.  Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140).

Authors:  E A Montalvo; C Grose
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

6.  Varicella-zoster virus (VZV) glycoprotein E is a serological antigen for detection of intrathecal antibodies to VZV in central nervous system infections, without cross-reaction to herpes simplex virus 1.

Authors:  Anna Grahn; Marie Studahl; Staffan Nilsson; Elisabeth Thomsson; Malin Bäckström; Tomas Bergström
Journal:  Clin Vaccine Immunol       Date:  2011-06-22

7.  Immunological diagnosis in viral infections of the central nervous system: course of antibody titres against homo- and heterologous viruses.

Authors:  R H Dennin; E Herb
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

8.  Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.

Authors:  E M Cantin; R Eberle; J L Baldick; B Moss; D E Willey; A L Notkins; H Openshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

9.  Deletion in open reading frame 49 of varicella-zoster virus reduces virus growth in human malignant melanoma cells but not in human embryonic fibroblasts.

Authors:  Tomohiko Sadaoka; Hironori Yoshii; Takayoshi Imazawa; Koichi Yamanishi; Yasuko Mori
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

10.  Use of baculovirus-expressed glycoprotein H in an enzyme-linked immunosorbent assay developed to assess exposure to chelonid fibropapillomatosis-associated herpesvirus and its relationship to the prevalence of fibropapillomatosis in sea turtles.

Authors:  Lawrence H Herbst; Shefali Lemaire; Ada R Ene; David J Heslin; Llewellyn M Ehrhart; Dean A Bagley; Paul A Klein; Jack Lenz
Journal:  Clin Vaccine Immunol       Date:  2008-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.